Table 1 Clinical information of ccRCC patients
Characteristic | Low expression of CX3CL1 | High expression of CX3CL1 | P value |
|---|---|---|---|
n | 269 | 270 | Â |
T stage, n (%) | Â | Â | < 0.001 |
 T1 | 113 (21%) | 165 (30.6%) |  |
 T2 | 39 (7.2%) | 32 (5.9%) |  |
 T3 | 107 (19.9%) | 72 (13.4%) |  |
 T4 | 10 (1.9%) | 1 (0.2%) |  |
N stage, n (%) | Â | Â | 0.132 |
 N0 | 126 (49%) | 115 (44.7%) |  |
 N1 | 12 (4.7%) | 4 (1.6%) |  |
M stage, n (%) | Â | Â | 0.042 |
 M0 | 212 (41.9%) | 216 (42.7%) |  |
 M1 | 49 (9.7%) | 29 (5.7%) |  |
Pathologic stage, n (%) | Â | Â | < 0.001 |
 Stage I | 110 (20.5%) | 162 (30.2%) |  |
 Stage II | 31 (5.8%) | 28 (5.2%) |  |
 Stage III | 74 (13.8%) | 49 (9.1%) |  |
 Stage IV | 52 (9.7%) | 30 (5.6%) |  |
Primary therapy outcome, n (%) | Â | Â | 0.010 |
 PD | 8 (5.4%) | 3 (2%) |  |
 SD | 0 (0%) | 6 (4.1%) |  |
 PR | 0 (0%) | 2 (1.4%) |  |
 CR | 49 (33.3%) | 79 (53.7%) |  |
Histologic grade, n (%) | Â | Â | < 0.001 |
 G1 | 1 (0.2%) | 13 (2.4%) |  |
 G2 | 94 (17.7%) | 141 (26.6%) |  |
 G3 | 116 (21.8%) | 91 (17.1%) |  |
 G4 | 52 (9.8%) | 23 (4.3%) |  |
Hemoglobin, n (%) | Â | Â | 0.002 |
 Elevated | 1 (0.2%) | 4 (0.9%) |  |
 Low | 152 (33.1%) | 111 (24.2%) |  |
 Normal | 82 (17.9%) | 109 (23.7%) |  |